• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CIDRAP- Analysis suggests HPV vaccine protects unvaccinated people through herd immunity

Lance

MPH, CSP & CIT Retired, CHMM Emeritus
www.cidrap.umn.edu/human-papillomav...ine-protects-unvaccinated-people-through-herd

Analysis suggests HPV vaccine protects unvaccinated people through herd immunity



Laine Bergeson


55 minutes ago.

Human Papillomavirus (HPV)
A new nationwide cohort study from Sweden suggests that widespread human papillomavirus (HPV) vaccination could substantially reduce the risk of precancerous lesions even among people who never received the vaccine.

The study, published in The Lancet Public Health, examined rates of high-grade cervical lesions (HSIL+) among more than 850,000 unvaccinated girls and women born from 1985 to 2000 by using national vaccination registries.

A team led by researchers from the Karolinska Institutet in Stockholm compared outcomes across cohorts exposed to different HPV vaccination strategies, including largely opportunistic vaccination (when people are offered a vaccine as part of a routine doctor visit or other interaction with the health care system), subsidized vaccination, catch-up vaccination, and school-based vaccination.

Among unvaccinated women born in 1999 or 2000 and eligible for school-based vaccination programs that attained coverage greater than 80%, HSIL+ incidence was about 50% lower than in unvaccinated women from birth cohorts before vaccination was widespread.

At age 23 years, the incidence rate ratio for the 1999–2000 cohort was 0.53 (95% confidence interval [CI], 0.39 to 0.77). In the subsidized vaccination cohort (1989–92), the age-adjusted incidence rate ratio was 1.18 (95% CI, 1.15 to 1.20). In the catch-up vaccination cohort (1993–98), the age-adjusted incidence rate ratio was 1.03 (0.99 to 1.06).

Vaccination sharply reduces precancerous lesions


Nearly all cervical cancers are caused by HPV infection, and vaccination has been shown to sharply reduce infections and precancerous lesions. Herd protection refers to the indirect benefit of HPV vaccines for unvaccinated people. When enough people are vaccinated, the virus’s overall spread in the community drops. As a result, unvaccinated women and girls are less likely to be exposed to HPV infection and related disease.

In an accompanying commentary, Nicolas Wentzensen, MD, PhD, of the National Cancer Institute, and Nicole Campos, PhD, of the Harvard T.H. Chan School of Public Health, caution that estimating herd effects is challenging, particularly because models of what disease rates would have looked like without vaccination do not exist. Differences in sexual behavior, screening practices, and immunologic differences across birth cohorts can complicate interpretation.

Still, Wentzensen and Campos write, “The models and observational data both suggest that there is a herd effect on the incidence of cervical lesions,” even as “the magnitude of this effect is difficult to establish.”

The study’s strengths include its large size and use of registry data, which help minimize selection bias. Plus, the extensive data source allows generalization to other countries with similar screening programs and HPV vaccination recommendations.

“Importantly,” write the study authors, “by studying cohorts exposed to different vaccination strategies, we were able to assess the varying effects of these programmes on unvaccinated women, providing valuable insights into the potential herd effects of HPV vaccination.”
 
Back
Top Bottom